The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s RYBREVANT (amivantamab-vmjw) in combination with chemotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that features epidermal growth factor receptor (EGFR) exon 19 deletions or L858R substitution mutations. This approval targets patients whose disease has […]
Xencor, Inc., a clinical-stage biopharmaceutical company specializing in engineered antibodies for cancer treatment, saw its stock rise by 26% to $20.39 on Monday following substantial updates on its research and development (R&D) efforts and promising results from a Phase 1 dose-escalation study. Despite the recent surge, the stock remains down about 5% for the year, […]
Instil Bio, Inc., a clinical-stage biopharmaceutical company headquartered in Dallas, Texas, is undergoing a significant restructuring that includes the closure of its Manchester, United Kingdom, operations and a complete workforce reduction in that region. This move comes as part of the company’s broader strategy to optimize costs and focus on high-impact projects in more strategically […]
AstraZeneca has received approval from the European Commission (EC) to use its cancer drug, Tagrisso (osimertinib), in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for adult patients with advanced epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). This approval is specifically for patients whose tumors exhibit exon 19 deletions or […]
RTW Biotech Opportunities Ltd, an investment company listed on the London Stock Exchange and specialized in the life sciences sector, is proud to announce its participation in the Series C financing round of Obsidian Therapeutics, Inc. The round successfully raised $160.5 million, a testament to the high growth potential seen in Obsidian’s innovative approaches to […]
Avistone Biotechnology Co. Ltd., a precision oncology therapeutics company, has announced the conditional approval from the National Medical Products Administration (NMPA) of China for commercializing Vebreltinib to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC). Pivotal Phase II Study Results Underpinning Approval The NMPA’s decision was influenced by the positive outcomes […]
In the latest development in oncology research, AstraZeneca’s PACIFIC-2 Phase III trial, involving Imfinzi (durvalumab) concurrently administered with platinum-based chemoradiotherapy (CRT), did not achieve statistical significance for its primary endpoint of progression-free survival (PFS) in treating patients with unresectable, Stage III non-small cell lung cancer (NSCLC). Imfinzi’s Established Role and PACIFIC-2’s Goals Despite this outcome, […]
Mirati Therapeutics, Inc. (NASDAQ: MRTX), an innovative biotechnology company, has received conditional authorization from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its KRAZATI (adagrasib) monotherapy. This approval marks a pivotal milestone for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) who present the KRASG12C mutation and have not […]
Genentech, a Roche Group member, has announced positive results from its Phase III ALINA study evaluating Alecensa (alectinib), setting a new standard for treating early-stage anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Meeting its primary endpoint of disease-free survival (DFS), Alecensa showed a statistically significant and clinically meaningful improvement compared to platinum-based chemotherapy. […]
Eli Lilly and Company (NYSE: LLY) has unveiled top-line results from the LIBRETTO-431 study, which focused on the assessment of Retevmo against platinum-based chemotherapy plus pemetrexed in patients diagnosed with RET fusion-positive advanced non-small cell lung cancer (NSCLC). The findings showcased a notable improvement in progression-free survival (PFS), a primary objective of the study. Study […]